Logo image of GRVI

GROVE INC (GRVI) Stock Fundamental Analysis

USA - NASDAQ:GRVI - US39959A1060 - Common Stock

4.95 USD
+0.35 (+7.61%)
Last: 8/18/2022, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, GRVI scores 3 out of 10 in our fundamental rating. GRVI was compared to 36 industry peers in the Personal Care Products industry. GRVI may be in some trouble as it scores bad on both profitability and health. GRVI is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GRVI was profitable.
GRVI Yearly Net Income VS EBIT VS OCF VS FCFGRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 2M -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA 9.78%
ROE 11.41%
ROIC 5.24%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRVI Yearly ROA, ROE, ROICGRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 -500 -1K -1.5K -2K

1.3 Margins

Industry RankSector Rank
OM 4.76%
PM (TTM) 8.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRVI Yearly Profit, Operating, Gross MarginsGRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

GRVI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, GRVI has more shares outstanding
Compared to 1 year ago, GRVI has an improved debt to assets ratio.
GRVI Yearly Shares OutstandingGRVI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M
GRVI Yearly Total Debt VS Total AssetsGRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 11.63 indicates that GRVI is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.00 indicates that GRVI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.63
ROIC/WACC0.69
WACC7.54%
GRVI Yearly LT Debt VS Equity VS FCFGRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 2.35 indicates that GRVI has no problem at all paying its short term obligations.
GRVI has a Quick Ratio of 1.53. This is a normal value and indicates that GRVI is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.53
GRVI Yearly Current Assets VS Current LiabilitesGRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 5M 10M 15M

More info and screens

8

3. Growth

3.1 Past

GRVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.14%, which is quite impressive.
GRVI shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.91%.
Measured over the past years, GRVI shows a very strong growth in Revenue. The Revenue has been growing by 230.19% on average per year.
EPS 1Y (TTM)147.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.63%
Revenue 1Y (TTM)91.91%
Revenue growth 3Y230.19%
Revenue growth 5YN/A
Sales Q2Q%61.82%

3.2 Future

The Earnings Per Share is expected to grow by 87.76% on average over the next years. This is a very strong growth
GRVI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.17% yearly.
EPS Next Y-65.83%
EPS Next 2Y44.89%
EPS Next 3Y56.16%
EPS Next 5Y87.76%
Revenue Next Year93.88%
Revenue Next 2Y93.01%
Revenue Next 3Y73.79%
Revenue Next 5Y70.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GRVI Yearly Revenue VS EstimatesGRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
GRVI Yearly EPS VS EstimatesGRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.94, the valuation of GRVI can be described as expensive.
GRVI is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.79, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 11.29, the valuation of GRVI can be described as reasonable.
GRVI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.21.
Industry RankSector Rank
PE 30.94
Fwd PE 11.29
GRVI Price Earnings VS Forward Price EarningsGRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.72
GRVI Per share dataGRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as GRVI's earnings are expected to grow with 56.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.89%
EPS Next 3Y56.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GROVE INC

NASDAQ:GRVI (8/18/2022, 8:00:01 PM)

4.95

+0.35 (+7.61%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)09-02 2022-09-02/bmo
Inst Owners4.83%
Inst Owner Change-96.13%
Ins Owners25.64%
Ins Owner Change0%
Market Cap79.74M
Analysts82.86
Price Target10.2 (106.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 30.94
Fwd PE 11.29
P/S 1.99
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB N/A
EV/EBITDA 20.72
EPS(TTM)0.16
EY3.23%
EPS(NY)0.44
Fwd EY8.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.49
BVpS1.76
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.78%
ROE 11.41%
ROCE N/A
ROIC 5.24%
ROICexc N/A
ROICexgc 9.74%
OM 4.76%
PM (TTM) 8.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.53
Altman-Z 11.63
F-Score7
WACC7.54%
ROIC/WACC0.69
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.63%
EPS Next Y-65.83%
EPS Next 2Y44.89%
EPS Next 3Y56.16%
EPS Next 5Y87.76%
Revenue 1Y (TTM)91.91%
Revenue growth 3Y230.19%
Revenue growth 5YN/A
Sales Q2Q%61.82%
Revenue Next Year93.88%
Revenue Next 2Y93.01%
Revenue Next 3Y73.79%
Revenue Next 5Y70.17%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A